Pro-apoptotic activity of BH3-only proteins and BH3 mimetics: From theory to potential cancer therapy

Anti-Cancer Agents in Medicinal Chemistry

Volumn 12, Issue 8, 2012, Pages 966-981

  Hartman, Mariusz L ^a   Czyz, Malgorzata ^a  

^a MEDICAL UNIVERSITY OF LODZ   (Poland)

Author keywords

ABT 737; Anti cancer therapy; Antimycin A; Apoptosis; Autophagy; Bcl 2 proteins; BH3 domain; BH3 mimetics; BH3 peptide; BH3 only proteins; Gossypol; HA14 1; Obatoclax; S1; SAHB; TW 37

Indexed keywords

BECLIN 1; BENDAMUSTINE; BH3 PROTEIN; CISPLATIN; CYCLOPHOSPHAMIDE; DOCETAXEL; ERLOTINIB; ETOPOSIDE; FLUDARABINE; GEMCITABINE; ISOSORBIDE; LENALIDOMIDE; MESSENGER RNA; NAVITOCLAX; OBATOCLAX; PACLITAXEL; PREDNISONE; PROTEIN BAX; PROTEIN BCL 2; PROTEIN BCL XL; PROTEIN BID; PROTEIN KINASE B; RITUXIMAB; TEMOZOLOMIDE;

ADRENAL CORTEX CARCINOMA; APOPTOSIS; AUTOPHAGY; BINDING AFFINITY; CANCER CELL; CANCER INVASION; CANCER PATIENT; CANCER THERAPY; CENTRAL NERVOUS SYSTEM TUMOR; CHRONIC LYMPHATIC LEUKEMIA; CLINICAL STUDY; DOWN REGULATION; ENDOPLASMIC RETICULUM; ESOPHAGUS CANCER; FOLLICULAR LYMPHOMA; GENE DELETION; GENE MUTATION; GENE TRANSLOCATION; GENETIC TRANSCRIPTION; HEAD AND NECK SQUAMOUS CELL CARCINOMA; HUMAN; INSULIN RELEASE; LUNG NON SMALL CELL CANCER; LUNG SMALL CELL CANCER; MITOCHONDRIAL MEMBRANE; MOLECULAR MIMICRY; NONHUMAN; PROSTATE CANCER; PROTEIN EXPRESSION; PROTEIN PROCESSING; PROTEIN PROTEIN INTERACTION; REVIEW; SIGNAL TRANSDUCTION; UPREGULATION;

ANTINEOPLASTIC AGENTS, PHYTOGENIC; APOPTOSIS; BIOLOGICAL PRODUCTS; BIOMIMETIC MATERIALS; DRUG SCREENING ASSAYS, ANTITUMOR; HUMANS; MOLECULAR STRUCTURE; NEOPLASMS; PROTO-ONCOGENE PROTEINS C-BCL-2; STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 84866373844     PISSN: 18715206     EISSN: 18755992     Source Type: Journal    
DOI: 10.2174/187152012802650084     Document Type: Review

References (169)

1. Kroemer, G.; Galluzzi, L.; Vandenabeele, P.; Abrams, J.; Alnemri, E.S.; Baehrecke, E.H.; Blagosklonny, M.V.; El-Deiry, W.S.; Golstein, P.; Green, D.R.; Hengartner, M.; Knight, R.A.; Kumar, S.; Lipton, S.A.; Malorni, W.; Nuñez, G.; Peter, M.E.; Tschopp, J.; Yuan, J.; Piacentini, M.; Zhivotovsky, B.; Melino, G. Classification of cell death: recommendations of the Nomenclature Committee on Cell Death 2009. Cell Death Differ., 2009, 16, 3-11.
2. Adams, J.M.; Cory, S. The Bcl-2 apoptotic switch in cancer development and therapy. Oncogene, 2007,26, 1324-1337.
3. Chipuk, J.E.; Moldoveanu, T.; Llambi, F.; Parsons, M.J.; Green, D.R. The Bcl-2 family reunion. Mol. Cell, 2010, 37, 299-310.
4. Sinha, S.; Levine, B. The autophagy effector Beclin 1: a novel BH3-only protein. Oncogene, 2009, 27, S137-S148.
5. Kamer, I.; Sarig, R.; Zaltsman, Y.; Niv, H.; Oberkovitz, G.; Regev, L.; Haimovich, G.; Lerenthal, Y.; Marcellus, R.C.; Gross, A. Proapoptotic BID is an ATM effector in the DNA-damage response. Cell, 2005, 122, 593-603.
6. Lomonosova, E.; Chinnadurai, G. BH3-oly proteins in apoptosis and beyond: an overview. Oncogene, 2009, 27, S2-S19.
7. Chen, L.; Willis, S.N.; Wei, A.; Smith, B.J.; Fletcher, J.I.; Hinds, M.G.; Colman, P.M.; Day, C.L.; Adams, J.M.; Huang, D.C.S. Differential targeting of prosurvival Bcl-2 proteins by their BH3only ligands allows complementary apoptotic function. Mol. Cell, 2005, 17, 393-403.
8. Cheng, E.H.Y.A.; Wei, M.C.; Weiler, S.; Flavell, R.A.; Mak, T.W.; Lindsten, T.; Korsmeyer, S.J. Bcl-2, Bcl-XL sequester BH3 domain-only molecules preventing BAX-and BAK-mediated mitochondrial apoptosis. Mol. Cell, 2001, 8, 705-711.
9. Gaviathotis, E.; Suzuki, M.; Davis, M.L.; Pitter, K.; Bird, G.H.; Katz, S.G.; Tu, H.C.; Kim, H.; Cheng, E.H.Y.; Tjandra, N.; Walensky, L.D. BAX activation is initiated at a novel interaction site. Nature, 2008, 455, 1076-1082.
10. Letai, A.; Bassik, M.C.; Walensky, L.D.; Sorcinelli, M.D.; Weiler, S.; Korsmeyer, S.J. Distinct BH3 domains either sensitize or activate mitochondrial apoptosis, serving as prototype cancer therapeutics. Cancer Cell, 2002, 2, 183-192.
11. Kim, H.; Tu, H.C.; Ren, D.; Takeuchi, O.; Jeffers, J.R.; Zambetti, G.P.; Hsieh, J.J.D.; Cheng, E.H.Y. Stepwise activation of BAX and BAK by tBID, BIM and PUMA initiates mitochondrial apoptosis. Mol. Cell, 2009, 36, 487-499.
12. Chonghaile, T.N.; Letai, A. Mimicking the BH3 domain to kill cancer cells. Oncogene, 2009, 27, S149-S157.
13. Giam, M.; Huang, D.C.S.; Bouillet, P. BH3-only proteins and their roles in programmed cell death. Oncogene, 2009, 27, S128-S136.
14. Kuroda, J.; Taniwaki, M. Involvement of BH3-only proteins in hematologic malignancies. Crit. Rev. Oncol. Hematol., 2009, 71, 89-101.
15. Elkholi, R.; Floros, K.V.; Chipuk, J.E. The role of BH3-only proteins in tumor cell development, signaling and treatment. Genes Cancer, 2011, 2, 523-537.
16. Certo, M.; Del Gaizo Moore, V.; Nishino, M.; Wei, G.; Korsmeyer, S.; Armstrong, S.A.; Letai, A. Mitochondria primed by death signals determine cellular addiction to antiapoptotic BCL-2 family members. Cancer Cell, 2006, 9, 351-365.
17. Leber, B.; Lin, J.; Andrews, D.W. Embedded together: The life and death consequences of interaction of the Bcl-2 family with membranes. Apoptosis, 2007, 12, 897-911.
18. Shamas-Din, A.; Brahmbhatt, H.; Leber, B.; Andrews, D.W. BH3only proteins: Orchestrators of apoptosis. Biochem. Biophys. Acta, 2011, 1813, 508-520.
19. Czabotar, P.E.; Lee, E.F.; van Delft, M.F.; Day, C.L.; Smith, B.J.; Huang, D.C.S.; Fairlie, W.D.; Hinds, M.G.; Colman, P.M. Structural insights into the degradation of Mcl-1 induced by BH3 mimetics. Proc. Natl. Acad. Sci. USA, 2007, 104, 6217-6222.
20. Mund, T.; Gewies, A.; Schoenfeld, N.; Bauer, M.K.A.; Grimm, S. Spike, a novel BH3-only protein, regulates apoptosis at the endoplasmic retikulum. FASEB J., 2003, 17, 696-698.
21. Chinnadurai, G.; Vijayalingam, S.; Gibson, S.B. BNIP3 subfamily BH3-only proteins: mitochondrial stress sensors in normal and pathological functions. Oncogene, 2009, 27, S114-S127.
22. Zhu, Y.; Zhao, L.; Liu, L.; Gao, P.; Tian, W.; Wang, X.; Jin, H.; Xu, H.; Chen Q. Beclin 1 cleavage by caspase-3 inactivates autophagy and promotes apoptosis. Protein Cell, 2010, 1, 468-477.
23. Junttila, M.R.; Evan, G.I. p53 -a Jack of all trades but master of none. Nat. Rev. Cancer, 2009, 9, 811-829.
24. Lowe, S.W.; Cepero, E.; Evan, G. Intrinsic tumour suppression. Nature, 2004, 432, 307-315.
25. Ham, J.; Towers, E.; Gilley, J.; Terzano, S.; Randall, R. BH3-only proteins: key regulators of neuronal apoptosis. Cell Death Differ., 2005, 12, 1015-1020.
26. Hübner, A.; Cavanagh-Kyros, J.; Rincon, M.; Flavell, R.A.; Davis, R.J. Functional cooperation of the proapoptotic Bcl2 family proteins Bmf and Bim in vivo. Mol. Cell. Biol., 2010, 30, 98-105.
27. Fricker, M.; O'Prey, J.; Tolkovsky, A.M.; Ryan, K.M. Phosphorylation of Puma modulates its apoptotic function by regulating protein stability. Cell Death Dis., 2010, 1, e59.
28. Luciano, F.; Jacquel, A.; Colosetti, P.; Herrant, M.; Cagnol, S.; Pages, G.; Auberger, P. Phosphorylation of Bim-EL by Erk1/2 on serine 69 promotes its degradation via the proteasome pathway and regulates its proapoptotic function. Oncogene, 2003, 22, 6785-6793.
29. Zalckvar, E.; Berissi, H.; Mizrachy, L.; Idelchuk, Y.; Koren, I.; Eisenstein, M.; Sabany, H.; Pinkas-Kramarski, R.; Kimchi, A. DAP-kinase-mediated phosphorylation on the BH3 domain of beclin 1 promotes dissociation of beclin 1 from Bcl-XL and induction of autophagy. EMBO Rep., 2009, 10, 285-292.
30. Verma, S.; Zhao, L.J.; Chinnadurai, G. Phosphorylation of the proapoptotic protein BIK. J. Biol.Chem., 2001, 276, 4671-4676.
31. Real, P.J.; Sanz, C.; Gutierrez, O.; Pipaon, C.; Zubiaga, A.M.; Fernandez-Luna, L.L. Transcriptional activation of the proapoptotic bik gene by E2F proteins in cancer cells. FEBS Lett., 2006, 580, 5905-5909.
32. Billen, L.P.; Shamas-Din, A.; Andrews, D.W. Bid: a Bax-like BH3 protein. Oncogene, 2009, 27, S93-S104.
33. Walensky, L.D.; Pitter, K.; Morash, J.; Oh, K.J.; Barbuto, S.; Fisher, J.; Smith, E.; Verdine, G.L.; Korsmeyer, S.J. A stapled BID BH3 helix directly binds and activates BAX. Mol. Cell, 2006, 24, 199-210.
34. Hu, X.; Han, Z.; Wyche, J.H.; Hendrickson, E.A. Helix 6 of tBid is necessary but not sufficient for mitochondrial binding activity. Apoptosis, 2003, 8, 277-289.
35. Portt, L.; Norman, G.; Clapp, C.; Greenwood, M.; Greenwood, M.T. Anti-apoptosis and cell survival: A review. Biochim. Biophys. Acta, 2011, 1813, 238-259.
36. Chen-Levy, Z.; Nourse, J.; Cleary, M.L. The bcl-2 candidate protooncogene product is a 24-kilodalton integral-membrane protein highly expressed in lymphoid cell lines and lymphomas carrying the t(14;18) translocation. Mol. Cell. Biol., 1989, 9, 701-710.
37. Hanahan, D.; Weinberg, R.A. The hallmarks of cancer: the next generation. Cell, 2011, 144, 646-674.
38. Nakamura, M.; Ishida, E.; Shimada, K.; Nakase, H.; Sakaki, T.; Konisi, N. Frequent HRK inactivation associated with low apoptotic index in secondary glioblastomas. Acta Neuropathol., 2005, 110, 402-410.
39. Aita, V.M.; Liang, X.H.; Murty, V.V.V.S.; Pincus, D.L.; Yu, W.; Cayanis, E.; Kalachikov, S.; William, T.C.; Levine, B. Cloning and genomic organization of Beclin 1, a candidate tumor suppressor gene on chromosome 17q21. Genomics, 1999, 59, 59-65.
40. Goldstein, N.B.; Johannes, W.U.; Gadeliya, A.V.; Green, M.R.; Fujita, M.; Norris, D.A.; Shellman, Y.G. Active N-Ras and B-Raf inhibit anoikis by downregulating Bim expression in melanocytic cells. J. Invest. Dermatol., 2009, 129, 432-437.
41. Keuling, A.M.; Andrew, S.E.; Tron, V.A. Inhibition of p38 MAPK enhances ABT-737-induced cell death in melanoma cell lines: novel regulation of PUMA. Pigment Cell Melanoma Res., 2010, 23, 430-440.
42. Shao, Y.; Aplin, A.E. Akt3-mediated resistance to apoptosis in BRAF-targeted melanoma cells. Cancer Res., 2010, 70, 6670-6681.
43. Van Delft, M.F.; Wei, A.H.; Mason, K.D.; Vandenberg, C.J.; Chen, L.; Czabotar, P.E.; Willis, S.N.; Scott, C.L.; Day, C.L.; Cory, S.; Adams, J.M.; Roberts, A.W.; Huang, D.C.S. The BH3 mimetic ABT-737 targets selective Bcl-2 proteins and efficiently induces apoptosis via Bak/Bax if Mcl-1 is neutralized. Cancer Cell, 2006, 10, 389-399.
44. Finnegan, N.M.; Curtin, J.F.; Prevost, G.; Morgan, B.; Cotter, T.G. Induction of apoptosis in prostate carcinoma cells by BH3 peptides which inhibit Bak/Bcl-2 interactions. Br. J. Cancer, 2001, 85, 115-121.
45. Walensky, L.D.; Kung, A.L.; Escher, I.; Malia, T.J.; Barbuto, S.; Wright, R.D.; Wagner, G.; Verdine, G.L.; Korsmeyer, S.J. Activation of apoptosis in vivo by a hydrocarbon-stapled BH3 helix. Science, 2004, 305, 1466-1470.
46. Stewart, M.L.; Fire, E.; Keating, A.E.; Walensky, L.D. The MCL-1 BH3 helix is an exclusive MCL-1 inhibitor and apoptosis sensitizer. Nat. Chem. Biol., 2010, 6, 595-601.
47. Yang, B.; Liu, D.; Huang, Z. Synthesis and helical structure of lactam bridged BH3 peptides derived from pro-apoptotic Bcl-2 family proteins. Bioorg. Med. Chem. Lett., 2004, 14, 1403-1406.
48. Lee, E.F.; Smith, B.J.; Horne, W.S.; Mayer, K.N.; Evangelista, M.; Colman, P.M.; Gellman, S.H.; Fairlie, W.D. Structural basis of Bcl-XL recognition by a BH3-mimetic α/β-peptide generated by sequence-based design. Chembiochem., 2011, 12, 2025-2032.
49. Goldsmith, K.C.; Liu, X.; Dam, V.; Morgan, B.T.; Shabbout, M.; Cnaan, A.; Letai, A.; Korsmeyer, S.J.; Hogarty, M.D. BH3 peptidomimetics potently activate apoptosis and demonstrate single agent efficacy in neuroblastoma. Oncogene, 2006, 25, 4525-4533.
50. Ponassi, R.; Biasotti, B.; Tomati, V.; Bruno, S.; Poggi, A.; Malacarne, D.; Cimoli, G.; Salis, A.; Pozzi, S.; Miglino, M.; Damonte, G.; Cozzini, P.; Spyraki, F.; Campanini, B.; Bagnasco, L.; Castagnino, N.; Tortolina, L.; Mumot, A.; Frassoni, F.; Daga, A.; Cilli, M.; Piccardi, F.; Monfardini, I.; Perugini, M.; Zoppoli, G.; D'Arrigo, C.; Pesenti, R.; Parodi, S. A novel Bim-BH3-derived Bcl-XL inhibitor. Cell Cycle, 2008, 7, 3211-3224.
51. Liu, Y.; Li, Y.; Wang, H.; Yu, J.; Lin, H.; Xu, D.; Wang, Y.; Liang, A.; Liang, X.; Zhang, X.; Fu, M.; Qian, H.; Lin, C. BH3-based fusion artificial peptide induces apoptosis and targets human colon cancer. Mol. Ther., 2009, 17, 1509-1516.
52. Oliver, C.L.; Miranda, M.B.; Shangary, S.; Land, S.; Wang, S.; Johnson, D.E. (-)-Gossypol acts directly on the mitochondria to overcome Bcl-2-and Bcl-XL-mediated apoptosis resistance. Mol. Cancer Ther., 2005, 4, 23-31.
53. Etxebarria, A.; Landeta, O.; Antonsson, B.; Basañez, G. Regulation of antiapoptotic MCL-1 function by gossypol: mechanistic insights from in vitro reconstituted systems. Biochem. Pharmacol., 2008, 76, 1563-1576.
54. Priyadarshi, A.; Roy, A.; Kim, K.S.; Kim, E.E.; Hwang, K.Y. Structural insights into mouse anti-apoptotic Bcl-xl reveal affinity for Beclin 1 and gossypol. Biochem. Biophys. Res. Commun., 2010, 394, 515-521.
55. Chang, J.S.; Hsu, Y.L.; Kuo, P.L.; Chiang, L.C.; Lin, C.C. Upregulation of Fas/Fas ligand-mediated apoptosis by gossypol in an immortalized human alveolar lung cancer cell line. Clin. Exp. Pharmacol. Physiol., 2004, 31, 716-722.
56. Macoska, J.A.; Adsule, S.; Tantivejkul, K.; Wang, S.; Pienta, K.J.; Lee, C.T. -(-)Gossypol promotes the apoptosis of bladder cancer cells in vitro. Pharmacol. Res., 2008, 58, 323-331.
57. Tuszynski, G.P.; Cossu, G. Differential cytotoxic effect of gossypol on human melanoma, colon carcinoma, and other tissue culture cell lines. Cancer Res., 1984, 44, 768-771.
58. Gilbert, N.E.; O'Reilly, J.E.; Chang, C.J.G.; Lin, J.C.; Brueggemeier, W. Antiproliferative activity of gossypol and gossypolone on human breast cancer cells. Life Sci., 1995, 57, 61-67.
59. Wang, X.; Wang, J.; Wong, S.C.H.; Chow, L.S.N.; Nicholls, J.M.; Wong, Y.C.; Liu, Y.; Kwong, D.L.W.; Sham, J.S.T.; Tsao, S.W. Cytotoxic effect of gossypol on colon carcinoma cells. Life Sci., 2000, 67, 2663-2671.
60. Mohammad, R.M.; Wang, S.; Aboukameel, A.; Chen, B.; Wu, X.; Chen, J.; Al-Katib, A. Preclinical studies of a nonpeptidic smallmolecule inhibitor of Bcl-2 and Bcl-XL [(-)-gossypol] against diffuse large cell lymphoma. Mol. Cancer Ther., 2005, 4, 13-21.
61. Meng, Y.; Li, Y.; Li, J.; Li, H.; Fu, J.; Liu, Y.; Liu, H.; Chen, X.G. (-)Gossypol and its combination with imatinib induce apoptosis in human chronic myeloid leukemic cells. Leuk. Lymphoma, 2007, 48, 2204-2212.
62. Balakrishnan, K.; Burger, J.A.; Wierda, W.G.; Gandhi, V. AT-101 induces apoptosis in CLL B cells and overcomes stromal cellmediated Mcl-1 induction and drug resistance. Blood, 2009, 113, 149-153.
63. Paoluzzi, L.; Gonen, M.; Gardner, J.R.; Mastrella, J.; Yang, D.; Holmlund, J.; Sorensen, M.; Leopold, L.; Manova, K.; Marcucci, G.; Heaney, M.L.; O'Connor, O.A. Targeting Bcl-2 family members with the BH3 mimetic AT-101 markedly enhances the therapeutic effects of chemotherapeutic agents in in vitro and in vivo models of B-cell lymphoma. Blood, 2008, 111, 5350-5358.
64. Huang, Y.W.; Wang, L.S.; Dowd, M.K.; Wan, P.J.; Lin, Y.C. (-)-Gossypol reduces invasiveness in metastatic prostate cancer cells. Anticancer Res., 2009, 29, 2179-2188.
65. Kasten-Pisula, U.; Windhorst, S.; Dahm-Daphi, J.; Mayr, G.; Dikomey, E. Radiosensitization of tumour cell lines by the polyphenol Gossypol results from depressed double-strand break repair and not from enhanced apoptosis. Radiother. Oncol., 2007, 83, 296-303.
66. Moon, D.O.; Kim, M.O.; Choi, Y.H.; Lee, H.G.; Kim, N.D.; Kim, G.Y. Gossypol suppresses telomerase activity in human leukemia cells via regulating hTERT. FEBS Lett., 2008, 582, 3367-3373.
67. Moon, D.O.; Choi, Y.H.; Moon, S.K.; Kim, W.J.; Kim, G.Y. Gossypol decreases tumor necrosis factor-α-induced intercellular adhesion molecule-1 expression via suppression of NF-κB activity. Food Chem. Toxicol., 2011, 49, 999-1005.
68. Moon, D.O.; Kim, M.O.; Lee, J.D.; Kim, G.Y. Gossypol suppresses NF-κB activity and NF-κB-related gene expression in human leukemia U937 cells. Cancer Lett., 2008, 264, 192-200.
69. Lei, X.; Chen, Y.; Du, G.; Yu, W.; Wang, X.; Qu, H.; Xia, B.; He, H.; Mao, J.; Zong, W.; Liao, X.; Mehrpour, M.; Hao, X.; Chen, Q. Gossypol induces Bax/Bak-independent activation of apoptosis and cytochrome c release via a conformational change in Bcl-2. FASEB J., 2006, 20, E1510-E1519.
70. Wang, Y.C.; Rao, P.N. Effect of gossypol on DNA synthesis and cell cycle progression of mammalian cells in vitro. Cancer Res., 1984, 44, 35-38.
71. Hutchinson, R.W.; Ing, N.H.; Burghardt, R.C. Induction of c-fos, and cytochrome c oxidase subunits I and II by gossypol acetic acid in rat liver cells. Cell Biol. Toxicol., 1998, 14, 391-399.
72. Hou, D.X.; Uto, T.; Tong, X.; Takeshita, T.; Tanigawa, S.; Imamura, I.; Ose, T.; Fujii, M. Involvement of reactive oxygen species-independent mitochondrial pathway in gossypol-induced apoptosis. Arch. Biochem. Biophys., 2004, 428, 179-187.
73. Gao, P.; Bauvy, C.; Souquère, S.; Tonelli, G.; Liu, L.; Zhu, Y.; Qiao, Z.; Bakula, D.; Proikas-Cezanne, T.; Pierron, G.; Codogno, P.; Chen, Q.; Mehrpour, M. The Bcl-2 homology domain 3 mimetic gossypol induces both beclin 1-dependent and beclin 1-independent cytoprotective autophagy in cancer cells. J. Biol. Chem., 2010, 285, 25570-25581.
74. Lian, J.; Wu, X.; He, F.; Karnak, D.; Tang, W.; Meng, Y.; Xiang, D.; Ji, M.; Lawrence, T.S.; Xu, L. A natural BH3 mimetic induces autophagy in apoptosis-resistant prostate cancer via modulating Bcl-2-Beclin1 interaction at endoplasmic retikulum. Cell Death Differ., 2011, 18, 60-71.
75. Huang, L.H.; Hu, J.Q.; Tao, W.Q.; Li, Y.H.; Li, G.M.; Xie, P.Y.; Liu, X.S.; Jiang, J. Gossypol inhibits phosphorylation of Bcl-2 in human leukemia HL-60 cells. Eur. J. Pharmacol., 2010, 645, 9-13.
76. Deoras, D.P.; Young-Curtis, P.; Dalvi, R.R.; Tippett, F.E. Effect of gossypol on hepatic and serum γ-glutamyltransferase activity in rats. Vet. Res. Commun., 1997, 21, 317-323.
77. Quintana, P.J.E.; de Peyster, A.; Klatzke, S.; Park, H.J. Gossypolinduced DNA breaks in rat lymphocytes are secondary to cytotoxicity. Toxicol. Lett., 2000, 117, 85-94.
78. Barba-Barajas, M.; Hernández-Flores, G.; Lerma-Díaz, J.M.; Ortiz-Lazareno, P.C.; Domínguez-Rodríguez, J.R.; Barba-Barajas, L.; de Celis, R.; Jave-Suarez, L.F.; Aguilar-Lemarroy, A.C.; Guevara-Barraza, M.G.; Bravo-Cuellar, A. Gossypol induced apoptosis of polymorphonuclear leukocytes and monocytes: Involvement of mitochondrial pathway and reactive oxygen species. Immunopharmacol. Immunotoxicol., 2009, 31, 320-330.
79. Bushunow, P.; Reidenberg, M.M.; Wasenko, J.; Winfield, J.; Lorenzo, B.; Lemke, S.; Himpler, B.; Corona, R.; Coyle, T. Gossypol treatment of recurrent adult malignant gliomas. J. Neurooncol., 1999, 43, 79-86.
80. Van Poznak, C.; Seidman, A.D.; Reidenberg, M.M.; Moasser, M.M.; Sklarin, N.; van Zee, K.; Borgen, P.; Gollub, M.; Bacotti, D.; Yao, T.J.; Bloch, R.; Ligueros, M.; Sonenberg, M.; Norton, L.; Hadis, C. Oral gossypol in the treatment of patients with refractory metastatic breast cancer: A phase I/II clinical trial. Breast Cancer Res. Treat., 2001, 66, 239-248.
81. Manion, M.K.; O'Neill, J.W.; Giedt, C.D.; Kim, K.M.; Zhang, K.Y.Z.; Hockenbery, D.M. Bcl-XL mutations suppress cellular sensitivity to antimycin A. J. Biol. Chem., 2004, 279, 2159-2165.
82. King, M.A. Antimycin A-induced killing of HL-60 cells: apoptosis initiated from within mitochondria does not necessarily proceed via caspase 9. Cytometry Part A, 2005, 63A, 69-76.
83. Han, Y.H.; Park, W.H. Growth inhibition in antimycin A treatedlung cancer Calu-6 cells via inducing a G1 phase arrest and apoptosis. Lung Cancer, 2009, 65, 150-160.
84. Oltersdorf, T.; Elmore, S.W.; Shoemaker, A.R.; Armstrong, R.C.; Augeri, D.J.; Belli, B.A.; Bruncko, M.; Deckwerth, T.L.; Dinges, J.; Hajduk, P.J.; Joseph, M.K.; Kitada, S.; Korsmeyer, S.J.; Kunzer, A.R.; Letai, A.; Li, C.; Mitten, M.J.; Nettesheim, D.G.; Ng, S.; Nimmer, P.M.; O'Connor, J.M.; Oleksijew, A.; Petros, A.M.; Reed, J.C.; Shen, W.; Tahir, S.K.; Thompson, C.B.; Tomaselli, K.J.; Wang, B.; Wendt, M.D.; Zhang, H.; Fesik, S.W.; Rosenberg, S.H. An inhibitor of Bcl-2 family proteins induces regression of solid tumours. Nature, 2005, 435, 677-681.
85. Huang, S.; Sinicrope, F.A. BH3 mimetic ABT-737 potentiates TRAIL-mediated apoptotic signaling by unsequestering Bim and Bak in human pancreatic cancer cells. Cancer Res., 2008, 68, 2944-2951.
86. Kang, M.H.; Kang, Y.H.; Szymanska, B.; Wilczynska-Kalak, U.; Sheard, M.A.; Harned, T.M.; Lock, R.B.; Reynolds, C.P. Activity of vincristine, L-ASP, and dexamethasone against acute lymphoblastic leukemia is enhanced by the BH3-mimetic ABT-737 in vitro and in vivo. Blood, 2007, 110, 2057-2066.
87. Zheng, L.; Yang, W.; Zhang, C.; Ding, W.J.; Zhu, H.; Lin, N.M.; Wu, H.H.; He, Q.J.; Yang, B. GDC-0941 sensitizes breast cancer to ABT-737 in vitro and in vivo through promoting the degradation of Mcl-1. Cancer Lett., 2011, 309, 27-36.
88. Keuling, A.M.; Felton, K.E.A.; Parker, A.A.M.; Akbari, M.; Andrew, S.E.; Tron, V.A. RNA silencing of Mcl-1 enhances ABT-737-mediated apoptosis in melanoma: role for a caspase-8-dependent pathway. PLoS ONE, 2009, 4, e6651: Available from: http://www.plosone.org/article/info%3Adoi%2F10.1371%2Fjournal.pone.0006651
89. Song, J.H.; Kandasamy, K.; Kraft, A.S. ABT-737 induces expression of the death receptor 5 and sensitizes human cancer cells to TRAIL-induced apoptosis. J. Biol. Chem., 2008, 283, 25003-25013.
90. Mason, K.D.; Vandenberga, C.J.; Scott, C.L.; Wei, A.H.; Cory, S.; Huang, D.C.S.; Robert, A.W. In vivo efficacy of the Bcl-2 antagonist ABT-737 against aggressive Myc-driven lymphomas. Proc. Natl. Acad. Sci. USA, 2008, 105, 17961-17966.
91. Gallenne, T.; Gautier, F.; Oliver, L.; Hervouet, E.; Noël, B.; Hickman, J.A.; Geneste, O.; Cartron, P.F.; Vallette, F.M.; Manon, S.; Juin, P. Bax activation by the BH3-only protein Puma promotes cell dependence on antiapoptotic Bcl-2 family members. J. Cell Biol., 2009, 185, 279-290.
92. Buron, N.; Porceddu, M.; Brabant, M.; Desgue, D.; Racoeur, C.; Lassalle, M.; Péchoux, C.; Rustin, P.; Jacotot, E.; Borgne-Sanchez, A. Use of human cancer cell lines mitochondria to explore the mechanisms of BH3 peptides and ABT-737-induced mitochondrial membrane permeabilization. PloS ONE, 2010, 5, e9924: Available from: http://www.plosone.org/article/info%3Adoi%2F10.1371%2Fjournal.pone.0009924
93. Yecies, D.; Carlson, N.E.; Deng, J.; Letai, A. Acquired resistance to ABT-737 in lymphoma cells that up-regulate MCL-1 and BFL-1. Blood, 2010, 115, 3304-3313.
94. Chen, S.; Dai, Y.; Harada, H.; Dent, P.; Grant, S. Mcl-1 down-regulation potentiates ABT-737 lethality by cooperatively inducing Bak activation and Bax translocation. Cancer Res., 2007, 67, 782-791.
95. Konopleva, M.; Contractor, R.; Tsao, T.; Samudio, I.; Ruvolo, P.P.; Kitada, S.; Deng, X.; Zhai, D.; Shi, Y.X.; Sneed, T.; Verhaegen, M.; Soengas, M.; Ruvolo, V.R.; McQueen, T.; Schober, W.D.; Watt, J.C.; Jiffar, T.; Ling, X.; Marini, F.C.; Harris, D.; Dietrich, M.; Estrov, Z.; McCubrey, J.; May, W.S.; Reed, J.C.; Andreeff, M. Mechanisms of apoptosis sensitivity and resistance to the BH3 mimetic ABT-737 in acute myeloid leukemia. Cancer Cell, 2006, 10, 375-388.
96. Tahir, S.K.; Yang, X.; Anderson, M.G.; Morgan-Lappe, S.E.; Sarthy, A.V.; Chen, J.; Warner, R.B.; Ng, S.C.; Fesik, S.W.; Elmore, S.W.; Rosenberg, S.H.; Tse, C. Influence of Bcl-2 family members on the cellular response of small-cell lung cancer cell lines to ABT-737. Cancer Res., 2007, 67, 1176-1183.
97. Miller, L.A.; Goldstein, N.B.; Johannes, W.U.; Walton, C.H.; Fujita, M.; Norris, D.A.; Shellman, Y.G. BH3 mimetic ABT-737 and a proteasome inhibitor synergistically kill melanomas through Noxa-dependet apoptosis. J. Invest. Dermatol., 2009, 129, 964-971.
98. Kuroda, J.; Kimura, S.; Andreeff, M.; Ashihara, E.; Kamitsuji, Y.; Yokota, A.; Kawata, E.; Takeuchi, M.; Tanaka, R.; Murotani, Y.; Matsumoto, Y.; Tanaka, H.; Strasser, A.; Taniwaki, M.; Maekawa, T. ABT-737 is a useful component of combinatory chemotherapies for chronic myeloid leukaemias with diverse drug-resistance mechanisms. Br. J. Haematol., 2007, 140, 181-190.
99. Okumura, K.; Huang, S.; Sinicrope, F.A. Induction of Noxa sensitizes human colorectal cancer cells expressing Mcl-1 to the small-molecule Bcl-2/Bcl-xL inhibitor, ABT-737. Clin. Cancer Res., 2008, 14, 8132-8142.
100. Weber, A.; Kirejczyk, Z.; Potthoff, S.; Ploner, C.; Häcker, G. Endogenous Noxa determines the strong proapoptotic synergism of the BH3-mimetic ABT-737 with chemotherapeutic agents in human melanoma cells. Transl. Oncol., 2009, 2, 73-83.
101. Maiuri, M.C.; Criollo, A.; Tasdemir, E.; Vicencio, J.M.; Tajeddine, N.; Hickman, J.A.; Geneste, O.; Kroemer, G. BH3-only proteins and BH3 mimetics induce autophagy by competitively disrupting the interaction between Beclin 1 and Bcl-2/Bcl-XL. Autophagy, 2007, 3, 374-376.
102. Harrison, L.R.E.; Micha, D.; Brandenburg, M.; Simpson, K.L.; Morrow, C.J.; Denneny, O.; Hodgkinson, C.; Yunus, Z.; Dempsey, C.; Roberts, D.; Blackhall, F.; Makin, G.; Dive, C. Hypoxic human cancer cells are sensitized to BH-3 mimetic-induced apoptosis via downregulation of the Bcl-2 protein Mcl-1. J. Clin. Invest., 2011, 121, 1075-1087.
103. Cragg, M.S.; Kuroda, J.; Puthalakath, H.; Huang, D.C.S.; Strasser, A. Gefitinib-induced killing of NSCLC cell lines expressing mutant EGFR requires BIM and can be enhanced by BH3 mimetics. PLoS Med., 2007, 4, e316: Available from: http://www.plosmedicine.org/article/info%3Adoi%2F10.1371%2Fjournal.pmed.0040316
104. Witham, J.; Valenti, M.R.; De-Haven-Brandon, A.K.; Vidot, S.; Eccles, S.A.; Kaye, S.B.; Richardson, A. The Bcl-2/Bcl-XL family inhibitor ABT-737 sensitizes ovarian cancer cells to carboplatin. Clin. Cancer Res., 2007, 13, 7191-7198.
105. Hann, C.L.; Daniel, V.C.; Sugar, E.A.; Dobromilskaya, I.; Murphy, S.C.; Cope, L.; Lin, X.; Hierman, J.S.; Wilburn, D.L.; Watkins, D.N.; Rudin, C.M. Therapeutic efficacy of ABT-737, a selective inhibitor of BCL-2, in small cell lung cancer. Cancer Res., 2008, 68, 2321-2328.
106. Li, R.; Zang, Y.; Li, C.; Patel, N.S.; Grandis, J.R.; Johnson, D.E. ABT-737 synergizes with chemotherapy to kill head and neck squamous cell carcinoma cells via a Noxa-mediated pathway. Mol. Pharmacol., 2009, 75, 1231-1239.
107. Cragg, M.S.; Jansen, E.S.; Cook, M.; Harris, C.; Strasser, A.; Scott, C.L. Treatment of B-RAF mutant human tumor cells with a MEK inhibitor requires Bim and is enhanced by a BH3 mimetic. J. Clin. Invest., 2008, 118, 3651-3659.
108. Oakes, S.R.; Vaillant, F.; Lim, E.; Lee, L.; Breslin, K.; Feleppa, F.; Deb, S.; Ritchie, M.E.; Takano, E.; Ward, T.; Fox, S.B.; Generali, D.; Smyth, G.K.; Strasser, A.; Huang, D.C.S.; Visvader, J.E.; Lindeman, G.J. Sensitization of BCL-2-expressing breast tumors to chemotherapy by the BH3 mimetic ABT-737. Proc. Natl. Acad. Sci. USA, 2011, in press: Available from: http://www.pnas.org/content/early/2011/07/13/1104778108.long
109. Jóna, A.; Khaskhely, N.; Buglio, D.; Shafer, J.A.; Derenzini, E.; Bollard, C.M.; Medeiros, L.J.; Illés, A.; Ji, Y.; Younes, A. The histone deacetylase inhibitor entinostat (SNDX-275) induces apoptosis in Hodgkin lymphoma cells and synergizes with Bcl-2 family inhibitors. Exp. Hematol., 2011, 39, 1007-1017.
110. Begley, J.; Vo, D.D.; Morris, L.F.; Bruhn, K.W.; Prins, R.M.; Mok, S.; Koya, R.C.; Garban, H.J.; Comin-Anduix, B.; Craft, N.; Ribas, A. Immunosensitization with a Bcl-2 small molecule inhibitor. Cancer Immunol. Immunother., 2009, 58, 699-708.
111. Reynoso, D.; Nolden, L.K.; Yang, D.; Dumont, S.N.; Conley, A.P.; Dumont, A.G.P.; Zhou, K.; Duensing, A.; Trent, J.C. Synergistic induction of apoptosis by the Bcl-2 inhibitor ABT-737 and imatinib mesylate in gastrointestinal stromal tumor cells. Mol. Oncol., 2011, 5, 93-104.
112. Del Gaizo Moore, V.; Brown, J.R.; Certo, M.; Love, T.M.; Novina, C.D.; Letai, A. Chronic lymphocytic leukemia requires BCL2 to sequester prodeath BIM, explaining sensitivity to BCL2 antagonist ABT-737. J. Clin. Invest., 2007, 117, 112-121.
113. Vogler, M.; Butterworth, M.; Majid, A.; Walewska, R.J.; Sun, X.M.; Dyer, M.J.S.; Cohen, G.M. Concurrent up-regulation of BCL-XL and BCL2A1 induces approximately 1000-fold resistance to ABT-737 in chronic lymphocytic leukemia. Blood, 2009, 113, 4403-4413.
114. Carrington, E.M.; Vikstrom, I.B.; Light, A.; Sutherland, R.M.; Londrigan, S.L.; Mason, K.D.; Huang, D.C.S.; Lew, A.M.; Tarlinton, D.M. BH3 mimetics antagonizing restricted prosurvival Bcl-2 proteins represent another class of selective immune modulatory drugs. Proc. Natl. Acad. Sci. USA, 2010, 107, 10967-10971.
115. Trudel, S.; Stewart, A.K.; Li, Z.; Shu, Y.; Liang, S.B.; Trieu, Y.; Reece, D.; Paterson, J.; Wang, D.; Wen, X.Y. The Bcl-2 family protein inhibitor, ABT-737, has substantial antimyeloma activity and shows synergistic effect with dexamethasone and melphalan. Clin. Cancer Res., 2007, 13, 621-629.
116. Del Gaizo Moore, V.; Schlis, K.D.; Sallan, S.E.; Armstrong, S.A.; Letai, A. BCL-2 dependence and ABT-737 sensitivity in acute lymphoblastic leukemia. Blood, 2008, 111, 2300-2309.
117. Tse, C.; Shoemaker, A.R.; Adickes, J.; Anderson, M.G.; Chen, J.; Jin, S.; Johnson, E.F.; Marsh, K.C.; Mitten, M.J.; Nimmer, P.; Roberts, L.; Tahir, S.K.; Xiao, Y.; Yang, X.; Zhang, H.; Fesik, S.; Rosenberg, S.H.; Elmore, S.W. ABT-263: a potent and orally bioavailable Bcl-2 family inhibitor. Cancer Res., 2008, 68, 3421-3428.
118. Shoemaker, A.R.; Mitten, M.J.; Adickes, J.; Ackler, S.; Refici, M.; Ferguson, D.; Oleksijew, A.; O'Connor, J.M.; Wang, B.; Frost, D.J.; Bauch, J.; Marsh, K.; Tahir, S.K.; Yang, X.; Tse, C.; Fesik, S.W.; Rosenberg, S.H.; Elmore, S.W. Activity of the Bcl-2 family inhibitor ABT-263 in a panel of small cell lung cancer xenograft models. Clin. Cancer Res., 2008, 14, 3268-3277.
119. Tahir, S.K.; Wass, J.; Joseph, M.K.; Devanarayan, V.; Hensler, P.; Hang, H.; Elmore, S.W.; Kroemer, P.E.; Tse, C.; Rosenberg, S.H.; Anderson, M.G. Identification of expression signatures predictive of sensitivity to the Bcl-2 family member inhibitor ABT-263 in small cell lung carcinoma and leukemia/lymphoma cell lines. Mol. Cancer Ther., 2010, 9, 545-557.
120. Vogler, M.; Dickens, D.; Dyer, M.J.S.; Owen, A.; Pirmohamed, M.; Cohen, G.M. The B-cell lymphoma 2 (BCL2)-inhibitors, ABT737 and ABT-263, are substrates for P-glycoprotein. Biochem. Biophys. Res. Commun., 2011, 408, 344-349.
121. Vogler, M.; Furdas, S.D.; Jung, M.; Kuwana, T.; Dyer, M.J.S.; Cohen, G.M. Diminished sensitivity of chronic lymphocytic leukemia cells to ABT-737 and ABT-263 due to albumin binding in blood. Clin. Cancer Res., 2010, 16, 4217-4225.
122. Wilson, W.H.; O'Connor, O.A.; Czuczman, M.S.; LaCasce, A.S.; Gerecitano, J.F.; Leonard, J.P.; Tulpule, A.; Dunleavy, K.; Xiong, H.; Chiu, Y.L.; Cui, Y.; Busman, T.; Elmore, S.W.; Rosenberg, S.H.; Krivoshik, A.P.; Enschede, S.H.; Humerickhouse, R.A. Navitoclax, a targeted high-affinity inhibitor of BCL-2, in lymphoid malignancies: a phase 1 dose-escalation study of safety, pharmacokinetics, pharmacodynamics, and antitumour activity. Lancet Oncol., 2010, 11, 1149-1159.
123. O'Brien, S.M.; Claxton, D.F.; Crump, M.; Faderl, S.; Kipps, T.; Keating, M.J.; Viallet, J.; Cheson, B.D. Phase I study of obatoclax mesylate (GX15-070), a small molecule pan-Bcl-2 family antagonist, in patients with advanced chronic lymphocytic leukemia. Blood, 2009, 113, 299-305.
124. Huang, S.; Okumura, K.; Sinicrope, F.A. BH3 mimetic Obatoclax enhances TRAIL-mediated apoptosis in human pancreatic cancer cells. Clin. Cancer Res., 2009, 15, 150-159.
125. Mott, J.L.; Bronk, S.F.; Mesa, R.A.; Kaufmann, S.H.; Gores, G.J. BH3-only protein mimetic obatoclax sensitizes cholangiocarcinoma cells to Apo2L/TRAIL-induced apoptosis. Mol. Cancer Ther., 2008, 7, 2339-2347.
126. Pan, J.; Cheng, C.; Verstovsek, S.; Chen, Q.; Jin, Y.; Cao, Q. The BH3-mimetic GX15-070 induces autophagy, potentiates the cytotoxicity of carboplatin and 5-fluorouracil in esophageal carcinoma cells. Cancer Lett., 2010, 293, 167-174.
127. Smoot, R.L.; Blechacz, B.R.A.; Werneburg, N.W.; Bronk, S.F.; Sinicrope, F.A.; Sirica, A.E.; Gores, G.J. A Bax-mediated mechanism for Obatoclax-induced apoptosis of cholangiocarcinoma cells. Cancer Res., 2010, 70, 1960-1969.
128. Li, J.; Viallet, J.; Haura, E.B. A small molecule pan-Bcl-2 family inhibitor, GX15-070, induces apoptosis and enhances cisplatininduced apoptosis in non-small cell lung cancer cells. Cancer Chemother. Pharmacol., 2008, 61, 525-534.
129. Jiang, C.C.; Wroblewski, D.; Yang, F.; Hersey, P.; Zhang, X.D. Human melanoma cells under endoplasmic reticulum stress are more susceptible to apoptosis induced by the BH3 mimetic Obatoclax. Neoplasia, 2009, 11, 945-955.
130. Nguyen, M.; Marcellus, R.C.; Roulston, A.; Watson, M.; Serfass, L.; Madiraju, S.R.M.; Goulet, D.; Viallet, J.; Bélec, L.; Billot, X.; Acoca, S.; Purisima, E.; Wiegmans, A.; Cluse, L.; Johnstone, R.W.; Beauparlant, P.; Shore, G.C. Small molecule obatoclax (GX15-070) antagonizes MCL-1 and overcomes MCL-1-mediated resistance to apoptosis. Proc. Natl. Acad. Sci. USA, 2007, 104, 19512-19517.
131. Trudel, S.; Li, Z.H.; Rauw, J.; Tiedemann, R.E.; Wen, X.Y.; Stewart, A.K. Preclinical studies of the pan-Bcl inhibitor obatoclax (GX015-070) in multiple myeloma. Blood, 2007, 109, 5430-5438.
132. Crawford, N.; Chacko, A.D.; Savage, K.I.; McCoy, F.; Redmond, K.; Longley, D.B.; Fennell, D.A. Platinum resistant cancer cells conserve sensitivity to BH3 domains and obatoclax induced mitochondrial apoptosis. Apoptosis, 2011, 16, 311-320.
133. Konopleva, M.; Watt, J.; Contractor, R.; Tsao, T.; Harris, D.; Estrov, Z.; Bornmann, W.; Kantarjian, H.; Viallet, J.; Samudio, I.; Andreeff, M. Mechanisms of antileukemic activity of the novel Bcl-2 homology domain-3 mimetic GX15-070 (Obatoclax). Cancer Res., 2008, 68, 3413-3420.
134. Dean, E.J.; Cummings, J.; Roulston, A.; Berger, M.; Ranson, M.; Blackhall, F.; Dive, C. Optimization of circulating biomarkers of obatoclax-induced cell death in patients with small cell lung cancer. Neoplasia, 2011, 13, 339-347.
135. Heidari, N.; Hicks, M.A.; Harada, H. GX15-070 (obatoclax) overcomes glucocorticoid resistance in acute lymphoblastic leukemia through induction of apoptosis and autophagy. Cell Death Dis., 2010, 1, e76: Available from: http://www.nature.com/cddis/journal/v1/n9/full/cddis201053a.html
136. Pérez-Galán, P.; Roué, G.; López-Guerra, M.; Nguyen, M.; Villamor, N.; Montserrat, E.; Shore, G.C.; Campo, E.; Colomer, D. BCL-2 phosphorylation modulates sensitivity to the BH3 mimetic GX15-070 (Obatoclax) and reduces its synergistic interaction with bortezomib in chronic lymphocytic leukemia cells. Leukemia, 2008, 22, 1712-1720.
137. McCoy, F.; Hurwitz, J.; McTavish, N.; Paul, I.; Barnes, C.; O'Hagan, B.; Odrzywol, K.; Murray, J.; Longley, D.; McKerr, G.; Fennell, D.A. Obatoclax induces Atg7-dependent autophagy independent of beclin-1 and BAX/BAK. Cell Death Dis., 2010, 1, e108: Available from: http://www.nature.com/cddis/journal/v1/n12/full/cddis201086a.html
138. Hwang, J.J.; Kuruvilla, J.; Mendelson, D.; Pishvaian, M.J.; Deeken, J.F.; Siu, L.L.; Berger, M.S.; Viallet, J.; Marshall, J.L. Phase I dose finding studies of Obatoclax (GX15-070), a small molecule pan-BCL-2 family antagonist, in patients with advanced solid tumors or lymphoma. Clin. Cancer Res., 2010, 16, 4038-4045.
139. Paik, P.K.; Rudin, C.M.; Brown, A.; Rizvi, N.A.; Takebe, N.; Travis, W.; James, L.; Ginsberg, M.S.; Juergens, R.; Markus, S.; Tyson, L.; Subzwari, S.; Kris, M.G.; Krug, L.M. A phase I study of obatoclax mesylate, a Bcl-2 antagonist, plus topotecan in solid tumor malignancies. Cancer Chemother. Pharmacol., 2010, 66, 1079-1085.
140. Paik, P.K.; Rudin, C.M.; Pietanza, M.C.; Brown, A.; Rizvi, N.A.; Takebe, N.; Travis, W.; James, L.; Ginsberg, M.S.; Juergens, R.; Markus, S.; Tyson, L.; Subzwari, S.; Kris, M.G.; Krug, L.M. A phase II study of obatoclax mesylate, a Bcl-2 antagonist, plus topotecan in relapsed small cell lung cancer. Lung Cancer, 2011, 74, 481-485.
141. Becattini, B.; Kitada, S.; Leone, M.; Monosov, E.; Chandler, S.; Zhai, D.; Kipps, T.J.; Reed, J.C.; Pellecchia, M. Rational design and real time, in-cell detection of the proapoptotic activity of a novel compound targeting Bcl-XL. Chem. Biol., 2004, 11, 389-395.
142. Kitada, S.; Kress, C.L.; Krajewska, M.; Jia, L.; Pellecchia, M.; Reed, J.C. Bcl-2 antagonist apogossypol (NSC736630) displays single-agent activity in Bcl-2 transgenic mice and has superior efficacy with less toxicity compared with gossypol (NSC19048). Blood, 2008, 111, 3211-3219.
143. Verhaegen, M.; Bauer, J.A.; de la Vega, C.M.; Wang, G.; Wolter, K.G.; Brenner, J.C.; Nikolovska-Coleska, Z.; Bengtson, A.; Nair, R.; Elder, J.T.; van Brocklin, M.; Carey, T.E.; Bradford, C.R.; Wang, S.; Soengas, M.S. A novel BH3 mimetic reveals a mitogenactivated protein kinase-dependent mechanism of melanoma cell death controlled by p53 and reactive oxygen species. Cancer Res., 2006, 66, 11348-11359.
144. Mohammad, R.M.; Goustin, A.S.; Aboukameel, A.; Chen, B.; Banerjee, S.; Wang, G.; Nikolovska-Coleska, Z.; Wang, S.; Al-Katib, A. Preclinical studies of TW-37, a new nonpeptidic smallmolecule inhibitor of Bcl-2, in diffuse large cell lymphoma xenograft model reveal drug action on both Bcl-2 and Mcl-1. Clin. Cancer Res., 2007, 13, 2226-2235.
145. Ashimori, N.; Zeitlin, B.D.; Hang, Z.; Warner, K.; Turkiewicz, I.M.; Spalding, A.C.; Teknos, T.N.; Wang, S.; Nör, J.E. TW-37, a small-molecule inhibitor of Bcl-2, mediates S-phase cell cycle arrest and suppresses head and neck tumor angiogenesis. Mol. Cancer Ther., 2009, 8, 893-903.
146. Zeitlin, B.D.; Spalding, A.C.; Campos, M.S.; Ashimori, N.; Dong, Z.; Wang, S.; Lawrence, T.S.; Nör, J.E. Metronomic small molecule inhibitor of Bcl-2 (TW-37) is antiangiogenic and potentiates the antitumor effect of ionizing radiation. Int. J. Radiation Oncology Biol. Phys., 2010, 78, 879-887.
147. Wang, Z.; Azmi, A.S.; Ahmad, A.; Banerjee, S.; Wang, S.; Sarkar, F.H.; Mohammad, R.M. TW-37, a small-molecule inhibitor of Bcl-2, inhibits cell growth and induces apoptosis in pancreatic cancer: involvement of Notch-1 signaling pathway. Cancer Res., 2009, 69, 2757-2765.
148. Degterev, A.; Lugovskoy, A.; Cardone, M.; Mulley, B.; Wagner, G.; Mitchison, T.; Yuan, J. Identification of small-molecule inhibitors of interaction between the BH3 domain and Bcl-xL. Nat. Cell Biol., 2001, 3, 173-182.
149. Feng, W.Y.; Liu, F.T.; Patwari, Y.; Agrawal, S.G.; Newland, A.C.; Jia, L. BH3-domain mimetic compound BH3I-2' induces rapid damage to the inner mitochondria membrane prior to the cytochrome c release from mitochondria. Br. J. Haematol., 2003, 121, 332-340.
150. Hao, J.H.; Yu, M.; Liu, F.T.; Newland, A.C.; Jia, L. Bcl-2 inhibitors sensitize tumor necrosis factor-related apoptosisinducing ligand-induced apoptosis by uncoupling of mitochondrial respiration in human leukemic CEM cells. Cancer Res., 2004, 64, 3607-3616.
151. Ray, S.; Bucur, O.; Almasan, A. Sensitization of prostate carcinoma cells to Apo2L/TRAIL by a Bcl-2 family protein inhibitor. Apoptosis, 2005, 10, 1411-1418.
152. Mitsiades, C.S.; Hayden, P.; Kotoula, V.; McMillin, D.W.; McMullan, C.; Negri, J.; Delmore, J.E.; Poulaki, V.; Mitsiades, N. Bcl-2 overexpression in thyroid carcinoma cells increases sensitivity to Bcl-2 homology 3 domain inhibition. J. Clin. Endocrinol. Metab., 2007, 92, 4845-4852.
153. Hetschko, H.; Voss, V.; Senft, C.; Seifert, V.; Prehn, J.H.M.; Kögel, D. BH3 mimetics reactivate autophagic cell death in anoxiaresistant malignant glioma cells. Neoplasia, 2008, 10, 873-885.
154. Wang, L.; Kong, F.; Kokoski, C.L.; Andrews, D.W.; Xing, C. Development of dimeric modulators for anti-apoptotic Bcl-2 proteins. Bioorg. Med. Chem. Lett., 2008, 18, 236-240.
155. Chen, J.; Freeman, A.; Liu, J.; Dai, Q.; Lee, R.M. The apoptotic effect of HA14-1, a Bcl-2-interacting small molecular compound, requires Bax translocation and is enhanced by PK11195. Mol. Cancer Ther., 2002, 1, 981-987.
156. Pei, X.Y.; Dai, Y.; Grant, S. The proteasome inhibitor bortezomib promotes mitochondrial injury and apoptosis induced by the small molecule Bcl-2 inhibitor HA14-1 in multiple myeloma cells. Leukemia, 2003, 17, 2036-2045.
157. Moon, D.O.; Kim, M.O.; Kang, S.H.; Choi, Y.H.; Park, S.Y.; Kim, G.Y. HA14-1 sensitizes TNF-α-induced apoptosis via inhibition of the NF-κB signaling pathway: Involvement of reactive oxygen species and JNK. Cancer Lett., 2010, 292, 111-118.
158. Pei, X.Y.; Dai, Y.; Grant, S. The small-molecule Bcl-2 inhibitor HA14-1 interacts synergistically with flavopiridol to induce mitochondrial injury and apoptosis in human myeloma cells through a free radical-dependent and Jun NH2-terminal kinase-dependent mechanism. Mol. Cancer Ther., 2004, 3, 1513-1524.
159. Reiners Jr, J.J.; Kassel, D. Susceptibility of myelomonocytic leukemia U937 cells to the induction of apoptosis by the non-peptidic Bcl-2 ligand HA14-1 is cell cycle phase-dependent. Cancer Lett., 2005, 221, 153-163.
160. Hamada, N.; Kataoka, K.; Sora, S.; Hara, T.; Omura-Minamisawa, M.; Funayama, T.; Sakashita, T.; Nakano, T.; Kobayashi, Y. The small-molecule Bcl-2 inhibitor HA14-1 sensitizes cervical cancer cells, but not normal fibroblasts, to heavy-ion radiation. Radiother. Oncol., 2008, 89, 227-230.
161. Skommer, J.; Wlodkowic, D.; Mättö, M.; Eray, M.; Pelkonen, J. HA14-1, a small molecule Bcl-2 antagonist, induces apoptosis and modulates action of selected anticancer drugs in follicular lymphoma B cells. Leuk. Res., 2006, 30, 322-331.
162. Mohan, N.; Karmakar, S.; Choudhury, S.R.; Banik, N.L.; Ray, S.K. Bcl-2 inhibitor HA14-1 and genistein together adeptly down regulated survival factors and activated cysteine proteases for apoptosis in human malignant neuroblastoma SK-N-BE2 and SHSY5Y cells. Brain Res., 2009, 1283, 155-166.
163. Arisan, E.D.; Kutuk, O.; Tezil, T.; Telci, D.; Basaga, H. Small inhibitor of Bcl-2, HA14-1, selectively enhanced the apoptotic effect of cisplatin by modulating Bcl-2 family members in MDA-MB-231 breast cancer cells. Breast Cancer Res. Treat., 2010, 119, 271-281.
164. Tian, D.; Das, S.G.; Doshi, J.M.; Peng, J.; Lin, J.; Xing, C. sHA 14-1, a stable and ROS-free antagonist against anti-apoptotic Bcl-2 proteins, bypasses drug resistances and synergizes cancer therapies in human leukemia cell. Cancer Lett., 2008, 259, 198-208.
165. Zhang, Z.; Song, T.; Zhang, T.; Gao, J.; Wu, G.; An, L.; Du, G. A novel BH3 mimetic S1 potently induces Bax/Bak-dependent apoptosis by targeting both Bcl-2 and Mcl-1. Int. J. Cancer, 2011, 128, 1724-1735.
166. Zhang, Z.; Jin, L.; Qian, X.; Wei, M.; Wang, Y.; Wang, J.; Yang, Y.; Xu, Q.; Xu, Y.; Liu, F. Novel Bcl-2 inhibitors: discovery and mechanism study of small organic apoptosis-inducing agents. Chembiochem., 2007, 8, 113-121.
167. Petros, A.M.; Huth, J.R., Oost, T.; Park, C.M.; Ding, H.; Wang, X.; Zhang, H.; Nimmer, P.; Mendoza, R.; Sun, C.; Mack, J.; Walter, K.; Dorwin, S.; Gramling, E.; Ladror, U.; Rosenberg, S.H.; Elmore, S.W.; Fesik, S.W.; Hajduk, P.J. Discovery of a potent and selective Bcl-2 inhibitor using SAR by NMR. Bioorg. Med. Chem. Lett., 2010, 20, 6587-6591.
168. Porter, J.; Payne, A.; de Candole, B.; Ford, D.; Hutchinson, B.; Trevitt, G.; Turner, J.; Edwards, C.; Watkins, C.; Whitcombe, I.; Davis, J.; Stubberfield, C. Tetrahydroisoquinoline amide substituted phenyl pyrazoles as selective Bcl-2 inhibitors. Bioorg. Med. Chem. Lett., 2009, 19, 230-233.
169. Malik, S.A.; Orhon, I.; Morselli, E.; Criollo, A.; Shen, S.; Mariño, G.; BenYounes, B.; Bénit, P.; Rustin, P.; Maiuri, M.C.; Kroemer, G. BH3 mimetics activate multiple pro-autophagic pathways. Oncogene, 2011, 30, 3918-3929.